Oncotelic Therapeutics Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Vuong Trieu

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	10.8yrs
Eigendom CEO	24.5%
Management gemiddelde ambtstermijn	5yrs
Gemiddelde ambtstermijn bestuur	geen gegevens

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Vuong Trieu's beloning veranderd ten opzichte van Oncotelic Therapeutics's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$5m
Jun 30 2024	n/a	n/a	-US$1m
Mar 31 2024	n/a	n/a	-US$8m
Dec 31 2023	n/a	n/a	-US$8m
Sep 30 2023	n/a	n/a	-US$12m
Jun 30 2023	n/a	n/a	-US$13m
Mar 31 2023	n/a	n/a	US$9m
Dec 31 2022	US$129k	US$38k	US$5m
Sep 30 2022	n/a	n/a	US$9m
Jun 30 2022	n/a	n/a	US$8m
Mar 31 2022	n/a	n/a	-US$11m
Dec 31 2021	US$257k	US$190k	-US$9m
Sep 30 2021	n/a	n/a	-US$11m
Jun 30 2021	n/a	n/a	-US$11m
Mar 31 2021	n/a	n/a	-US$8m
Dec 31 2020	US$216k	US$169k	-US$10m
Sep 30 2020	n/a	n/a	-US$10m
Jun 30 2020	n/a	n/a	-US$9m
Mar 31 2020	n/a	n/a	-US$10m
Dec 31 2019	US$259k	US$115k	-US$7m

Compensatie versus markt: Er zijn onvoldoende gegevens om vast te stellen of de totale vergoeding van Vuong redelijk is in vergelijking met bedrijven van vergelijkbare omvang in de US markt.

Compensatie versus inkomsten: De vergoeding van Vuong is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Vuong Trieu (61 yo)

10.8yrs

Tenure

Dr. Vuong Trieu, Ph.D. serves as the co-founder, President, Chairman and Chief Executive Officer of Oncotelic Inc. Dr. Trieu serves as Chairman and Chief Executive Officer of Oncotelic Therapeutics, Inc (f...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Vuong Trieu	Chairman & CEO	10.8yrs	geen gegevens	24.47% $ 2.5m
Amit Shah	Chief Financial Officer	5.3yrs	geen gegevens	0.088% $ 9.1k
Anthony Maida	Chief Medical Officer – Translation Medicine & Director	4.6yrs	geen gegevens	0.28% $ 28.9k
Saranjit Saund	CBO & GM of AI Division	5yrs	geen gegevens	4.05% $ 417.6k
Steven King	Consultant & Director	no data	geen gegevens	0% $ 0
Larn Hwang	Chief Scientific Officer	no data	geen gegevens	5.77% $ 595.2k
Seymour Fein	Chief Regulatory Officer & Chief Medical Officer	2.5yrs	geen gegevens	geen gegevens
Burcak Beser	CTO of AI Division	no data	geen gegevens	geen gegevens

5.0yrs

Gemiddelde duur

61yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van OTLC is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5 jaar).

Oncotelic Therapeutics Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Oncotelic Appoints Seymour Fein M.D. as Chief Regulatory Officer

Oncotelic Therapeutics, Inc. Appoints Fatih Uckun as Chief Medical Officer

Recent updates

Oncotelic Therapeutics, Inc. announced delayed 10-Q filing

Oncotelic Therapeutics, Inc. announced delayed annual 10-K filing

Oncotelic Therapeutics, Inc. Announces Linkage of Cancer and Lupus in Gliomas Patients

Oncotelic Therapeutics, Inc. announced delayed 10-Q filing

Oncotelic Therapeutics, Inc. announced delayed 10-Q filing

Oncotelic Announces Initiation of Clinical Study in Non-Small Lung Cell Cancer

Oncotelic Therapeutics, Inc. Initiates Clinical Trials Evaluating OT-101 against Metastatic Pancreatic Cancer

Oncotelic Therapeutics, Inc. Presents Clinical Data of Confirming TGF-BETA>2 as the Appropriate Target for Gliomas At JCA-AACR Meeting 2022

Oncotelic Therapeutics, Inc. announced delayed 10-Q filing

Oncotelic Initiates Clinical Trials Evaluating OT-101 Against Pediatric Gliomas

Oncotelic Therapeutics, Inc. announced delayed 10-Q filing

Oncotelic Therapeutics Receives FDA Clearance for Phase 2 Clinical Trial of OT-101/Pembroluzimab Combination for Mesothelioma (M201)

Oncotelic Therapeutics, Inc. announced delayed 10-Q filing

Oncotelic Appoints Seymour Fein M.D. as Chief Regulatory Officer

Oncotelic Therapeutics, Inc. Appoints Fatih Uckun as Chief Medical Officer

Oncotelic Therapeutics, Inc. announced delayed annual 10-K filing

Oncotelic Presenting OT-101 Oncology Program at Biotechgate Digital Partnering

Oncotelic Therapeutics, Inc. Initiates Phase 1 Trial Evaluating CA4P in Combination with Pembrolizumab for Melanoma

Oncotelic Announces ORF8 Mutations are Driving the Evolution of the Delta and the Omicron Variants

Oncotelic Therapeutics, Inc. announced that it has received $0.5 million in funding from Talos Victory Fund, LLC, Mast Hill Fund, L.P.

Oncotelic Announces Positive Topline Data for OT-101 C001 COVID Study

Oncotelic Therapeutics, Inc. Reports PulmoHealTM/ ArtiVedaTM Proven Active against Mild and Moderate COVID-19 Following the Preplanned Prospective Analysis of ARTI-19 Clinical Trial

Oncotelic Therapeutics, Inc. announced delayed 10-Q filing

Oncotelic Therapeutics, Inc. announced that it has received $0.6985 million in funding from Autotelic Inc.

Oncotelic Therapeutics, Inc. Closes Covid-19 Clinical Trial Early

Oncotelic Therapeutics, Inc. announced delayed 10-Q filing

Oncotelic Therapeutics, Inc. announced delayed annual 10-K filing

Mateon Announces Initiation of Phase 1B Clinical Trial on OT-101/IL-2 Combination Therapy for Solid Tumors

Mateon Therapeutics, Inc. Announces Enrollment Enrollment of its Sentinel Part 1 and Part 2 COVID-19

Mateon Therapeutics, Inc. and Windlas Biotech Limited Launches Pulmoheal™, A Combined Lung Therapy and Ai Telemedicine 360° Solution

Mateon Therapeutics, Inc. Partners with The Chopra Foundation for Development of PulmoHea and ARTIVeda

Mateon Therapeutics, Inc. Announces Completion of Arti-19 and Publication of Positive Interim Data

Mateon Therapeutics, Inc. Launches its Artificial Intelligence Telemedicine Platform for Post Marketing Survey to Support the Launch of its Drug Product, PulmoHealTM

Mateon Announces Positive Interim Results from ARTI-19 Clinical Trial Evaluating Covid-19 Therapeutic

Mateon Therapeutics and Windlas Biotech Enter into Definitive Agreement to Commercialze Artiveda™ Against Covid-19

Mateon Therapeutics, Inc. Announces the Receipt of Approval from Instituto Nacional De Salud (Ins), the Regulatory Agency of Peru, to Initiate the Company’s C001- Phase 2 Clinical Trial of OT-101

Mateon Therapeutics, Inc. Receives Approval from Republica Argentina for Phase 2 Global Study for OT-101

Mateon Therapeutics, Inc. Announces First Patient Enrolled in ARTI-19: A Multicenter Interventional Study of ArtiShield Against COVID-19

Mateon Therapeutics, Inc. and Windlas Biotech Limited Announce ArtiShield Is Now Approved for Manufacture and Marketing by the Ministry of AYUSH

Mateon Therapeutics, Inc. announced that it has received $2 million in funding

Analyse CEO-vergoeding

CEO

Tenure

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd